teriparatide (Forteo)

  • Pharmacy Author:
    Omudhome Ogbru, PharmD

    Dr. Ogbru received his Doctorate in Pharmacy from the University of the Pacific School of Pharmacy in 1995. He completed a Pharmacy Practice Residency at the University of Arizona/University Medical Center in 1996. He was a Professor of Pharmacy Practice and a Regional Clerkship Coordinator for the University of the Pacific School of Pharmacy from 1996-99.

  • Medical and Pharmacy Editor: Jay W. Marks, MD
    Jay W. Marks, MD

    Jay W. Marks, MD

    Jay W. Marks, MD, is a board-certified internist and gastroenterologist. He graduated from Yale University School of Medicine and trained in internal medicine and gastroenterology at UCLA/Cedars-Sinai Medical Center in Los Angeles.

View the Osteoporosis Slideshow Pictures

In animal studies some rats developed osteosarcoma, a type of bone cancer. Osteosarcoma is a rare but serious form of cancer rarely reported in patients taking teriparatide. To investigate if teriparatide increases the risk of osteosarcoma, a voluntary patient registry has been developed. Patients can get more information about this registry by calling 1-866-382-6813 or visiting www.forteoregistry.rti.org.


  • Patients with Paget's disease of bone, pediatric and young adult patients with open epiphyses (ends of long bones that are still growing), and patients with prior external beam or implant radiation involving the skeleton should not receive teriparatide.
  • Teriparatide should not be used for more than 2 years in a patient's lifetime and should not be given to patients with bone cancer, history of skeletal cancer, metabolic bone diseases other than osteoporosis, or hypercalcemic disorders.
  • Teriparatide may increase blood levels of calcium and uric acid. It may also increase calcium levels in urine.



PREPARATIONS: Prefilled multi-dose pen containing 600 mcg/2.4ml. Each dose is 20 mcg.

STORAGE: Teriparatide injection should be stored in the refrigerator between 2 C to 8 C (36 F to 4 F). Pens should be removed from the refrigerator only when ready to use and returned to the refrigerator right after use. Teriparatide injection should not be stored in the freezer.

DOSING: The recommended dose for all FDA approved indications is 20 mcg subcutaneously once a day. Teriparatide should be administered subcutaneously in either the thigh or stomach area. Teriparatide pens are preset to deliver 20 mcg of medicine with each injection.

The safety and effectiveness of teriparatide injection has not been studied beyond 2 years of treatment.

DRUG INTERACTIONS: Teriparatide injection should be used cautiously in patients taking digoxin (Lanoxin), a medication used to treat irregular heart rhythms. Teriparatide increases calcium in the blood and high levels of calcium may increase the risk for digoxin associated side effects. Teriparatide injection should be used cautiously with other medicines that may increase calcium in the blood.

Medically Reviewed by a Doctor on 6/19/2015

Quick GuideWhat Is Osteoporosis? Treatment, Symptoms, Medication in Pictures

What Is Osteoporosis? Treatment, Symptoms, Medication in Pictures
FDA Logo

Report Problems to the Food and Drug Administration

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

RxList Logo

Need help identifying pills and medications?

Use the pill identifier tool on RxList.

Subscribe to MedicineNet's Women's Health Newsletter

By clicking Submit, I agree to the MedicineNet's Terms & Conditions & Privacy Policy and understand that I may opt out of MedicineNet's subscriptions at any time.

Health Solutions From Our Sponsors